Targeted Inhibitors Successfully Resolve Refractory Mixed Histiocytosis Following Multiple Cranial Relapses In Elderly Patient

Elderly patient achieves full remission from mixed histiocytosis using BRAF and MEK inhibitors after multiple skull relapses and failed chemotherapy.

By: AXL Media

Published: Apr 16, 2026, 7:41 AM EDT

Source: Information for this report was sourced from Xia & He Publishing Inc.

Clinical Success With Targeted MAPK Pathway Inhibition

Medical researchers have documented the successful treatment of mixed histiocytosis in an elderly woman using a combination of targeted BRAF and MEK inhibitors. The patient, who suffered from both Langerhans cell histiocytosis and Erdheim-Chester disease, had previously failed to respond to multiple courses of conventional chemotherapy. According to the case report published in Oncology Advances, the introduction of reduced-dose dabrafenib and trametinib resulted in the total disappearance of all active lesions. This clinical outcome highlights the effectiveness of molecularly targeted therapies for complex histiocytic disorders that harbor the BRAF V600E mutation.

A Decadelong Progression From Cranial To Spinal Involvement

The patient’s medical history reveals a protracted diagnostic timeline, beginning with symptoms of polyuria and polydipsia five years before a formal LCH diagnosis in 2015. After the surgical removal of a temporal bone lesion, the patient experienced a series of relapses in the parietal skull and later the L2 vertebra. According to clinical records, the third relapse in 2024 was particularly significant, as biopsy results from the spinal lesion revealed a transition from unifocal LCH to a mixed histiocytosis pathology. This progression suggests that multiple skull relapses may serve as a precursor to more complex, multi-entity histiocytic diseases.

Diagnostic Complexity Of Mixed Histiocytic Neoplasms

Mixed histiocytosis is a recently recognized phenomenon where two or more distinct histiocytic neoplasms manifest in a single patient. In this specific case, the spinal lesion exhibited both CD1a+ areas typical of LCH and foamy histiocytes with Touton-like giant cells characteristic of ECD. According to the researchers, these diseases are hypothesized to arise from a common progenitor cell, often driven by mutations in the MAPK pathway. The patient notably lacked the classic systemic symptoms of ECD, such as retroperitoneal fibrosis or long bone pain, making the biopsy of the spinal lesion essential for an accurate diagnosis.